AU2010273708B2 - Vaccines and compositions against Streptococcus pneumoniae - Google Patents

Vaccines and compositions against Streptococcus pneumoniae Download PDF

Info

Publication number
AU2010273708B2
AU2010273708B2 AU2010273708A AU2010273708A AU2010273708B2 AU 2010273708 B2 AU2010273708 B2 AU 2010273708B2 AU 2010273708 A AU2010273708 A AU 2010273708A AU 2010273708 A AU2010273708 A AU 2010273708A AU 2010273708 B2 AU2010273708 B2 AU 2010273708B2
Authority
AU
Australia
Prior art keywords
seq
vaccine formulation
pneumoniae
polypeptides
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010273708A
Other languages
English (en)
Other versions
AU2010273708A1 (en
AU2010273708A8 (en
Inventor
Todd Gierahn
Richard Malley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Genocea Biosciences Inc
Original Assignee
Boston Children's Hospital
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Children's Hospital, Genocea Biosciences Inc filed Critical Boston Children's Hospital
Publication of AU2010273708A1 publication Critical patent/AU2010273708A1/en
Publication of AU2010273708A8 publication Critical patent/AU2010273708A8/en
Application granted granted Critical
Publication of AU2010273708B2 publication Critical patent/AU2010273708B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2010273708A 2009-06-29 2010-06-29 Vaccines and compositions against Streptococcus pneumoniae Ceased AU2010273708B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US22154109P 2009-06-29 2009-06-29
US61/221,541 2009-06-29
US24059809P 2009-09-08 2009-09-08
US24061609P 2009-09-08 2009-09-08
US61/240,616 2009-09-08
US61/240,598 2009-09-08
US31626710P 2010-03-22 2010-03-22
US61/316,267 2010-03-22
PCT/US2010/040406 WO2011008548A1 (en) 2009-06-29 2010-06-29 Vaccines and compositions against streptococcus pneumoniae

Publications (3)

Publication Number Publication Date
AU2010273708A1 AU2010273708A1 (en) 2012-02-23
AU2010273708A8 AU2010273708A8 (en) 2012-06-14
AU2010273708B2 true AU2010273708B2 (en) 2015-10-01

Family

ID=43449681

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010273708A Ceased AU2010273708B2 (en) 2009-06-29 2010-06-29 Vaccines and compositions against Streptococcus pneumoniae

Country Status (15)

Country Link
US (2) US10105412B2 (enExample)
EP (1) EP2448592B1 (enExample)
JP (1) JP5931724B2 (enExample)
KR (1) KR101748453B1 (enExample)
CN (2) CN107126557A (enExample)
AU (1) AU2010273708B2 (enExample)
BR (1) BRPI1011919A2 (enExample)
CA (1) CA2803061A1 (enExample)
IL (1) IL217166A0 (enExample)
IN (1) IN2012DN00791A (enExample)
MX (1) MX2012000158A (enExample)
NZ (1) NZ597858A (enExample)
RU (1) RU2580299C2 (enExample)
SG (2) SG10201403702SA (enExample)
WO (1) WO2011008548A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5931724B2 (ja) 2009-06-29 2016-06-08 ジェノセア バイオサイエンシーズ， インコーポレイテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2012085099A1 (en) * 2010-12-21 2012-06-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Determination of the efficacy of an anti-mycobacterial vaccination
SG10201600435UA (en) * 2011-01-20 2016-02-26 Genocea Biosciences Inc Vaccines And Compositions Against Streptococcus Pneumoniae
TW201249824A (en) * 2011-03-09 2012-12-16 Glaxosmithkline Llc Peptide deformylase inhibitors
RU2632651C2 (ru) * 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
US9765125B2 (en) 2012-01-20 2017-09-19 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against Streptococcus pneumoniae
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
US20150079132A1 (en) * 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
US10881729B2 (en) 2014-04-18 2021-01-05 Children's Medical Center Corporation Vaccine adjuvant compositions
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
BR112019014833A2 (pt) 2017-01-20 2020-04-14 Pfizer composições imunogênicas para uso em vacinas pneumococais
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
JP7354106B2 (ja) 2017-12-04 2023-10-02 インターベット インターナショナル ベー． フェー． レプリコン粒子および油性アジュバントによるワクチン接種
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
RU2728938C1 (ru) * 2020-05-06 2020-08-03 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) Применение даларгина для производства лекарственных средств профилактики пневмонии
EP4181951A1 (en) 2020-07-16 2023-05-24 Zalvac AB Streptococcal vaccines
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids
WO2004092209A2 (en) * 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
US20050136404A1 (en) * 1997-07-02 2005-06-23 Doucette-Stamm Lynn A. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
WO2006084467A1 (en) * 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
US20060210580A1 (en) * 2000-10-27 2006-09-21 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups A & B
US7384775B2 (en) * 2001-04-16 2008-06-10 Wyeth Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
JP2000511769A (ja) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション 新規化合物
AU745787B2 (en) 1997-05-06 2002-03-28 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
WO1998059071A1 (en) 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Lyme disease vaccines
US5882885A (en) * 1997-07-17 1999-03-16 Smithkline Beecham Corporation Glycogen phosphorylase
US5994101A (en) * 1997-07-18 1999-11-30 Smithkline Beecham Corporation DNA encoding gidA1 polypeptides
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
EP1144640A3 (en) 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
US6887480B1 (en) * 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
AU777856B2 (en) 1999-06-10 2004-11-04 Human Genome Sciences, Inc. Streptococcus pneumoniae proteins and vaccines
JP2003520034A (ja) * 1999-12-23 2003-07-02 ヴィマックス リミテッド ビルレンス遺伝子、タンパク質、およびそれらの用途
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP2275127B1 (en) * 2002-04-02 2012-09-19 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
US20090252756A1 (en) * 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
WO2004018646A2 (en) 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
AU2003268353A1 (en) 2002-08-30 2004-03-19 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
EP1828231A2 (en) 2004-12-22 2007-09-05 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus
AU2007225238A1 (en) * 2006-03-10 2007-09-20 Wyeth Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
CA2687375C (en) 2007-05-18 2017-08-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Primers and probes for the detection of streptococcus pneumoniae
WO2008146164A2 (en) 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
WO2008150885A1 (en) * 2007-05-29 2008-12-11 Board Of Regents, The University Of Texas System Modulation of the th-17 cell mediated immune responses
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2225265A2 (en) * 2007-09-14 2010-09-08 Katholieke Universiteit Leuven Streptococcus pneumoniae vaccines
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
WO2009114207A2 (en) * 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
US8313894B2 (en) 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
JP2012510289A (ja) 2008-12-03 2012-05-10 プロティア ワクチン テクノロジーズ リミテッド グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
US8658176B2 (en) * 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
US20120100172A1 (en) * 2009-06-25 2012-04-26 Michael Tal Immunogenic streptococcus pneumoniae peptides and peptide-multimers
JP5931724B2 (ja) 2009-06-29 2016-06-08 ジェノセア バイオサイエンシーズ， インコーポレイテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
WO2011064781A1 (en) 2009-11-30 2011-06-03 Ben-Gurion University Of The Negev Research And Development Authority S. pneumoniae adhesins
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5065434B2 (ja) * 2010-04-06 2012-10-31 株式会社日立製作所 管理方法及び管理装置
WO2011128892A2 (en) 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
WO2011141968A1 (en) 2010-05-14 2011-11-17 Hitachi, Ltd. Storage apparatus and data retaining method for storage apparatus
SG10201600435UA (en) * 2011-01-20 2016-02-26 Genocea Biosciences Inc Vaccines And Compositions Against Streptococcus Pneumoniae

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
US20050136404A1 (en) * 1997-07-02 2005-06-23 Doucette-Stamm Lynn A. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
US20080175854A1 (en) * 1997-07-02 2008-07-24 Genome Therapeutics, Inc. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
US20060210580A1 (en) * 2000-10-27 2006-09-21 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups A & B
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids
US7384775B2 (en) * 2001-04-16 2008-06-10 Wyeth Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
WO2004092209A2 (en) * 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
WO2006084467A1 (en) * 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TETTELIN, H. et al. "Complete Genome Sequence of a Virulent Isolate of Streptococcus pneumonia." Science, 2001. vol. 293, no. 5529, pages 498-506. *

Also Published As

Publication number Publication date
WO2011008548A8 (en) 2012-03-08
EP2448592A4 (en) 2013-04-24
CN102548572A (zh) 2012-07-04
AU2010273708A1 (en) 2012-02-23
CA2803061A1 (en) 2011-01-20
SG177402A1 (en) 2012-02-28
US10105412B2 (en) 2018-10-23
BRPI1011919A2 (pt) 2017-09-26
IN2012DN00791A (enExample) 2015-06-26
US20110020386A1 (en) 2011-01-27
US11207375B2 (en) 2021-12-28
NZ597858A (en) 2014-01-31
SG10201403702SA (en) 2014-09-26
WO2011008548A1 (en) 2011-01-20
IL217166A0 (en) 2012-02-29
RU2011153032A (ru) 2013-08-10
MX2012000158A (es) 2012-06-08
RU2580299C2 (ru) 2016-04-10
KR20120093141A (ko) 2012-08-22
EP2448592B1 (en) 2020-06-17
KR101748453B1 (ko) 2017-06-16
AU2010273708A8 (en) 2012-06-14
CN107126557A (zh) 2017-09-05
EP2448592A1 (en) 2012-05-09
JP2012532134A (ja) 2012-12-13
US20190298795A1 (en) 2019-10-03
JP5931724B2 (ja) 2016-06-08

Similar Documents

Publication Publication Date Title
US11207375B2 (en) Vaccines and compositions against Streptococcus pneumoniae
US10188717B2 (en) Vaccines and compositions against Streptococcus pneumoniae
US9765125B2 (en) Fused antigen vaccines and compositions against Streptococcus pneumoniae
BR112021004185A2 (pt) vacinas de proteína de fusão pneumocócica
HK1172254A (en) Vaccines and compositions against streptococcus pneumoniae
NZ614460B2 (en) Vaccines and compositions against streptococcus pneumoniae

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 26, NO 6, PAGE(S) 943 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME GENOCEA BIOSCIENCES, INC., APPLICATION NO. 2010273708, UNDER INID (72) CORRECT THE CO-INVENTOR TO GIERAHN, TODD

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired